Document Detail


Stable remissions in myasthenia gravis.
MedLine Citation:
PMID:  7192824     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Forty-two myasthenic patients received a total of 7.6 to 130 gm of cyclophosphamide over 2 to 37 months; 33 received prednisone concomitantly. Twenty-five (60%) are presently asympatomatic. Seventy-four percent improved after 1 month of therapy. Fifty-eight percent of those treated for a year, 86% of those treated for 2 years, and 100% of those treated for 32 months were asymptomatic. Based on our definition of remission (asymptomatic for at least 6 months without medication), 12 of the 16 patients (75%) followed for at least 18 months were in remission. Cyclophosphamide may have more specific therapeutic effects than other immunosuppressive drugs used to treat myasthenia.
Authors:
M C Perez; W L Buot; C Mercado-Danguilan; Z G Bagabaldo; L D Renales
Related Documents :
19701534 - Corticosteroid therapy for primary treatment of kawasaki disease - weight of evidence: ...
10571764 - Inhaled budesonide in acute asthma.
19825284 - Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with ...
2873744 - Polyangiitis overlap syndrome. classification and prospective clinical experience.
24071614 - Idiopathic macular hole: post-operative morpho-functional assessment and prognostic fac...
7209754 - Acute adhesive obstruction of the small intestine.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neurology     Volume:  31     ISSN:  0028-3878     ISO Abbreviation:  Neurology     Publication Date:  1981 Jan 
Date Detail:
Created Date:  1981-03-24     Completed Date:  1981-03-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  32-7     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Cyclophosphamide / administration & dosage,  therapeutic use*
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Myasthenia Gravis / drug therapy*,  therapy
Prednisone / administration & dosage,  therapeutic use*
Remission, Spontaneous
Thymectomy
Thymus Gland / radiation effects
Time Factors
Chemical
Reg. No./Substance:
50-18-0/Cyclophosphamide; 53-03-2/Prednisone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lateralization of brainstem lesions by brainstem auditory evoked potentials.
Next Document:  Comparative rates of local cerebral glucose utilization in the visual system of conscious albino and...